好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neurite Orientation Dispersion and Density Imaging (NODDI) and Immune System Response in Temporal Lobe Epilepsy
Epilepsy/Clinical Neurophysiology (EEG)
P4 - Poster Session 4 (5:00 PM-6:00 PM)
9-010

To examine the relationship between a noninvasive indirect neuroimaging of neuroinflammation (NODDI) and molecular and cellular biomarkers of peripheral inflammation in temporal lobe epilepsy (TLE). We hypothesized NODDI changes in the affected temporal lobe (aTL; ictal onset zone) will be associated with these biomarkers.   
Studies have shown that neuroinflammation is a primary contributor to seizure initiation and maintenance in TLE. We used whole-brain diffusion magnetic resonance imaging to identify abnormalities in multicompartment NODDI measures (FISO (free water), FICVF (neurite density), and ODI (neurite dispersion)) as a non-invasive proxy of neuroinflammation in TLE.
18 TLE and 18 healthy participants underwent 3T MRI HARDI protocol. FISO, FICVF and ODI statistical maps were generated for each participant. Two-sample t-tests (FDR corrected, p<0.05) were conducted to compare the two groups across these maps, focusing on the temporal region using a binary mask. Peripheral venous blood was collected at the time of imaging for biomarker testing. For each significant cluster identified, FISO, FICVF and ODI values were extracted for the TLE group and correlated with molecular and cellular biomarkers of peripheral inflammation.

We observed, mostly in the aTL, significantly higher FICVF values in healthy compared to TLE participants and higher ODI and FISO values in TLE compared to healthy participants. Multiple significant correlations (Spearman, p<0.05) were found between significant NODDI clusters and molecular and cellular biomarkers mostly in the aTL.

Developing non-invasive procedures to measure neuroinflammation has been a major focus of neuroimaging investigations in epilepsy. Such a technique would allow visualization of abnormal brain regions for possible surgical resection, and monitoring of disease course and treatment response. We report significant positive relationships between NODDI measures and peripheral molecular and cellular biomarkers of inflammation in the aTL, supporting NODDI as a possible measure of neuroinflammation in TLE.
Authors/Disclosures
Jerzy P. Szaflarski, MD, PhD, FAAN (University of Alabama At Birmingham)
PRESENTER 		Dr. Szaflarski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Szaflarski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LivaNova Inc. Dr. Szaflarski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PureTech Health. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Gidley, Sarli & Marusak, LLP. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Law Firm. Dr. Szaflarski has stock in AdCel Biopharma, LLC. Dr. Szaflarski has stock in iFovea.
Rodolphe Nenert Rodolphe Nenert has nothing to disclose.
Huixian Hong (University of Alabama At Birmingham) No disclosure on file
Christina Mueller, PhD Dr. Mueller has nothing to disclose.
Ayushe A. Sharma Mrs. Sharma has nothing to disclose.
Hongwei Qin, PhD Dr. Qin has nothing to disclose.
Etty Benveniste, PhD Dr. Benveniste has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SONTAG BRAIN TUMOR FOUNDATION. Dr. Benveniste has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for WINSHIP Cancer Center, Emory.